RenovoRx (RNXT) Gross Margin (2025 - 2026)
RenovoRx's (RNXT) quarterly Gross Margin came in at 84.27% in Q2 2026, up 2029.0% year-over-year from 3.96% in Q2 2025, and down 0.95% quarter-over-quarter from 85.08% in Q1 2026.
Powered by 
Analysis
RenovoRx (RNXT) Gross Margin (2025 - 2026) Analysis & Trends
RenovoRx has disclosed Gross Margin across 2 years of filings, most recently posting 84.27% for Q2 2026.
- In Q2 2026, Gross Margin rose 2029.0% year-over-year to 84.27%; the TTM figure through Jun 2026 stood at 84.41% (changed N/A YoY), while the FY2025 annual figure was 70.88%, down 2912.0% from the prior year.
- Gross Margin came in at 84.27% for Q2 2026 at RenovoRx, down from 85.08% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 88.24% in Q4 2025 to a low of 52.28% in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | 57.71% |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | 67.78% |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | 64.99% |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | 68.27% |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | 70.71% |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | 77.46% |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | 60.21% |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 63.44% |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | 45.84% |
| 10 | RenovoRx | 83.48 Mn | 83.48 Mn | 766,000.00 | 84.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 84.27% |
| Mar 31, 2026 | 85.08% |
| Dec 31, 2025 | 88.24% |
| Sep 30, 2025 | 80.08% |
| Jun 30, 2025 | 63.98% |
| Mar 31, 2025 | 52.28% |